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Abstract
The emergence of coronavirus disease 2019 (COVID-19) in December 2019 has resulted in over
20 million cases and 741,808 deaths globally, affecting more than 200 countries. COVID-19 was
declared a pandemic on 11 March 2020 by the World Health Organization. The disease is caused
by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). There is limited information
on COVID-19, and treatment has so far focused on supportive care and use of repurposed drugs.
COVID-19 can be transmitted via person-to-person contact through droplet spread. Some of the
recommended precautionary measures to reduce the rate of disease spread include social dis-
tancing, good hygiene practices, and avoidance of crowded areas. These measures are effective
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because the droplets are heavy and can only travel approximately 1 meter in the air, settling
quickly on fixed surfaces. Promising strategies to combat SARS-CoV-2 include discovery of ther-
apeutic targets/drugs and vaccines. In this review, we summarize the epidemiology, pathophysi-
ology, and diagnosis of COVID-19. We also address the mechanisms of action of approved
repurposed drugs for therapeutic management of the disease.
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Introduction
COVID-19 has become one of the most
dangerous pandemics in recent history.
The pandemic has claimed more than
740,000 lives, with more than 20 million
reported cases since the original outbreak.
The disease is caused by SARS-CoV-2, a
zoonotic pathogen that acquired mutations
as it crossed the species barrier from bat to
pangolin enabling it to infect humans.1
SARS-CoV-2 was confirmed as a novel
coronavirus using molecular methods and
initially named 2019 novel coronavirus
(2019-nCoV).2 The disease caused by this
virus was later renamed COVID-19 by the
World Health Organization (WHO).3
SARS-CoV-2 is highly infectious and has
spread to more than 200 countries in all
continents. Hence, the virus was declared
a global threat (pandemic) by the WHO.
SARS-CoV-2 has a single-stranded positive
sense RNA genome (þssRNA) approxi-
mately 30 kb long. The SARS-CoV-2
genome is organized similarly to those of
SARS-CoV-1 and Middle East respiratory
syndrome (MERS)-CoV.4 Using phyloge-
netic analysis, the SARS-CoV-2 genome
was demonstrated to share 96% sequence
similarity with a bat CoV genome.
SARS-CoV-2 belongs to the b-coronavirus
genus that includes SARS-CoV-1 and
MERS-CoV.5 The clinical symptoms
of COVID-19 include fever, cough, and
pneumonia, which makes the disease enor-
mously dangerous with a high case fatality
rate.6,7 In contrast to other b-coronavi-
ruses, many SARS-CoV-2 deaths have
resulted from multiple organ dysfunction
syndrome (MSOF) rather than respiratory
failure.8 This could be attributed to the
widespread distribution of angiotensin con-
verting enzyme-2 (ACE-2), the primary
receptor for SARS coronaviruses, in multi-
ple organs.9,10 ACE-2 is expressed as a cell-
surface molecule in the respiratory tract
(epithelium, arterial and venous endotheli-
um), the small intestinal epithelium, and
arterial smooth muscle cells.11
SARS-CoV-2 is morphologically spheri-
cal and is characterized by presence of a
spike protein, lower pathogenicity and
higher transmissibility between humans.12
Some of the primary measures taken to
reduce the number of infections and prevent
community transmission are to avoid
crowds and gatherings and to practice
good hygiene. Interestingly, countries with
the highest reported prevalence and mortal-
ity such as the United States, Spain, Italy,
the United Kingdom, Russia, Germany,
Brazil, France, Turkey, Iran and China,
are more concerned with flattening the
curve through early case detection,
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isolation, and development of therapeutic
drugs and vaccines. Because of the novel
nature of this disease, there is limited infor-
mation regarding risk factors for severe
outcomes. Specific factors such as the
serial interval, viral lifespan, incubation
period, pathogenic mechanisms, clinical
features and optimal disease management
remain unclear. Therefore, this review
aimed to summarize the epidemiology and
pathophysiology of SARS-CoV-2 as well as
the use of repurposed Food and Drug
Administration (FDA) approved drugs for
therapy. The entry of this virus into host
cells and possible downstream complica-
tions deserve closer attention.
Coronaviruses
CoVs are members of the subfamily
Othocoronavirinae of the family
Coronaviridae. The subfamily consist of
four genera: alpha, beta, gamma and delta
CoVs.13 Both alpha- and beta-CoVs can
infect mammals, including humans, while
the gamma- and delta-CoVs only infect
birds.14 About seven CoVs have been
isolated from humans (Figure 1). These
include two alpha-CoVs, human coronavi-
rus 229E (HCoV-229E) and human corona-
virus NL63 (HCoV-NL63), and five
beta-CoVs: human coronavirus OC43
(HCoV-OC43), human coronavirus HKU1
(HCoV-HKU1), SARS-CoV-1, MERS-
CoV, and SARS-CoV-2. SARS-CoV-1,
MERS-CoV, and SARS-CoV-2 are patho-
genic and cause severe infections in humans
following contact with the respective inter-
mediate hosts (bats) (Figure 2). However,
HCoV-229E, HCoV-NL63, HCoV-OC43,
and HCoV-HKU1 do not appear to cause
severe infections in humans.14
CoVs are enveloped viruses with
þssRNA genomes. They have the largest
genomes (approximately 26–33 kb) among
RNA viruses. All CoVs possess non-
segmented genomes with similar organiza-
tion.15 Generally, about two-thirds of the
genome consists of two large and overlap-
ping open reading frames (ORF1a and
ORF1b), which are translated into polypro-
teins pp1a and pp1ab and subsequently
processed to yield 16 non-structural pro-
teins (nsp1 to nsp16).16 The remaining
one-third of the genome consists of ORFs
encoding structural proteins including the
spike (S) glycoprotein embedded in the
envelope and the envelope (E), matrix
(M), and nucleoproteins (N).17 There are
short untranslated regions at both the 30
and 50 ends. The S protein plays a role in
receptor-binding and entry of virus into
host cells and is thus considered a major
therapeutic target. The M and E proteins
are important for viral assembly, while
the N protein is necessary for synthesis
of RNA.18
Overview of the SARS-CoV family
SARS-CoVs belongs to a global family of
viruses causing respiratory disease and
influenza-like symptoms such as fever,
muscle pain, sore throat, headache, and
cough.19 Figure 3 highlights the onset and
Figure 1. Alpha- and beta-coronaviruses in humans.
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progression of SARS-CoV-1, MERS-CoV,
and SARS-CoV-2 infection. The first case
of SARS-CoV-1, reported in China,
resulted in an outbreak that caused hun-
dreds of deaths and thousands of infected
cases in the early 2000s.20 A pneumonia-like
syndrome (MERS) was first discovered in
Saudi Arabia and then spread to several
countries, where it incurred a mortality
rate of about 3% to 6%. Marra et al (21)
observed that the MERS mortality rate
increased with age and was as high as
43% to 55% in people older than 60
years. In December 2019, SARS-CoV-2,
caused an outbreak in China and then
spread worldwide. The resulting disease
(COVID-19) is a serious threat mostly in
people with compromised immune systems
or underlying conditions such as lung dis-
ease, diabetes mellitus, and human immu-
nodeficiency virus infection.22
SARS-CoV-1. SARS-CoV-1 causes a viral
respiratory disease and belongs to lineage
B of the beta-CoVs.11 SARS-CoV-1 infec-
tion in humans was first reported in 2002
in China (Figure 3a). Within 1 year, it affect-
ed about 29 countries with about 8,422 cases
globally.13 Bats are the primary hosts of this
virus, with palm civets as intermediate hosts.
Humans are infected via direct contact with
intermediate hosts or through consumption
Figure 2. Mode of coronavirus transmission from carriers to humans.
Figure 3. Development of the (a) SARS-CoV-1, (b) MERS-CoV, and (c) SARS-CoV-2 epidemics.
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of uncooked meat, milk or urine, as shown
in Figure 2. Human-to-human infection also
occurred through nosocomial transmis-
sion.11 Symptoms of human SARS-CoV-1
infections include headache, fever and respi-
ratory complications such as cough, dys-
pnea, and pneumonia.23
The SARS-CoV-1 genome is 29,727
nucleotides in length. The 50 end of the
genome contains ORF1a and ORF1b.
The polyproteins encoded by these ORF
are auto-catalytically processed to yield a
number of viral proteases as well as the
RNA-dependent RNA polymerase (RdRp).
The remainder of the genome encodes the
viral structural proteins (S, E, M and N) as
well as several accessory proteins.18
The receptor for SARS-CoVs is ACE-2,
a surface molecule found on cells of the
respiratory tract, the small intestinal epithe-
lium, and smooth muscle. In the respiratory
tract, ACE-2 is expressed on epithelial cells
of the alveoli, bronchi, trachea, and bron-
chial serous glands, as well as on alveolar
monocytes and macrophages. The ACE-2
enzyme plays an important role in protec-
tion against lung failure.11
MERS-CoV. MERS-CoV causes a viral respi-
ratory disease and belongs to lineage C of
the beta-CoVs.11 The first cases of human
infection by MERS-CoV were reported in
Saudi Arabia in 2012. Cases were subse-
quently reported in other countries includ-
ing Qatar, Egypt, and the Republic of
Korea following contact with infected
camels (Figure 3b). Cases of MERS-CoV
were identified in about 27 countries
between 2012 and 2018.18 MERS-CoV
RNA in camels showed more than 99%
genomic sequence similarity to human
MERS-CoV.23 Bats are the natural hosts
of MERS-CoV (Figure 2), and a high prev-
alence of MERS-CoV infections in drome-
dary camels (intermediate hosts) was
confirmed in the Middle East, Spain, and
Africa. MERS-CoV infections were
transmitted to humans following contact
with camels infected with the virus.23
The MERS-CoV genome is about 30,119
nucleotides in length and has a 50 terminal
cap structure and a poly (A) tail at the 30
end. The genome encodes 16 non-structural
proteins (nsp1–nsp16) at the 50 end, four
structural proteins (S, E, M, and N) at the
30 end,24 and five accessory proteins in
ORF3, ORF4a, ORF4b, ORF5, and
ORF8.18 Risk factors for severe MERS-
CoV include age and the presence of under-
lying conditions such as diabetes, obesity,
hypertension, chronic renal disease, and
lung diseases.25
The receptor for MERS-CoV is dipep-
tidyl peptidase 4 (DPP4 or CD26). DPP4
is a multifunctional cell surface protein
and is expressed on the epithelial cells of
the respiratory tract, liver, kidney, small
intestine, and prostate, as well as on acti-
vated white blood cells. DPP4 also plays a
vital role in activation of T cells and pro-
viding co-stimulatory signals for immune
responses of T cells.11,18 Consequently,
MERS-CoV causes acute pneumonia and
renal dysfunction with associated clinical
symptoms such as cough, chest pain, sore
throat, fever, diarrhea, vomiting, and
abdominal pain. MERS-CoV can infect
human dendritic cells and macrophages in
vitro, thereby contributing to dysregulation
of the immune system.18
SARS-CoV-2. SARS-CoV-2, a newly discov-
ered coronavirus, has a þssRNA genome
and a spherical morphology when observed
under the electron microscope.26,27 SARS-
CoV-2 encodes a richly glycosylated spike
protein responsible for binding to the ACE-
2 receptor.28 The virion’s shape and the
ability of spike proteins to form a crown-
like structure gave coronaviruses their
name.29,30 The SARS-CoV-2 genetic mate-
rial is surrounded by a lipid-bilayer enve-
lope. Other structural components include
the nucleocapsids, membrane, envelope,
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and hemagglutinin. Unlike the envelope,
the membrane exists in higher quantities
within the virions.31 Among other func-
tions, the envelope serves to release viral
particles from the host cells.32 The nucleo-
capsid assist in RNA packaging during
virion assembly.33,34 Hemagglutinin enhan-
ces the entry and pathogenesis of coronavi-
ruses.33 Some of the characteristics of
SARS-CoV-2 are summarized in Table 1.
Many of these features are shared with
SARS-CoV-1. More information on the
epidemiology and general characteristics
of SARS-CoV-1 can be found later in the
review.
Other human coronaviruses
Other important human CoVs include
alpha-CoVs (HCoV-229E and HCoV-
NL63) and two beta-CoVs (HCoV-OC43
and HCoV-HKU1). The receptor for
HCoV-229E is human aminopeptidase N
(CD13), a cell-surface metalloprotease pre-
sent on cells of the kidney and lung, as well
as on epithelial and intestinal cells. The
receptor for HCoV-NL63 is also ACE-2.
The receptor for HCoV-OC43 is 9-O-acety-
lated sialic acid, while no receptor has been
identified for HCoV-HKU1.42,43
Generally, the most common diagnostic
tools for human CoVs are molecular detec-
tion techniques such as reverse
transcription-polymerase chain reaction
(RT-PCR) using RNA extracted from
respiratory tract samples as template.
Other methods include serological tests
and viral cultures.11 Although several
agents against CoVs, including antibodies,
antiviral peptides, and cell or viral protease
inhibitors, have been shown to be effective
both in vitro and/or in vivo, clinical trial
outcomes have not been reported.11
Therefore, clinical treatments for CoVs are
still lacking. Nevertheless, supportive and
symptomatic therapy are used for
Table 1. Biological characteristics of SARS-CoV-2 and COVID-19.
References
Name of disease COVID-19 [35]
Caused by SARS-CoV-2 [35–37]
Virus genus b-coronavirus [14]
Virus composition RNA, Spike protein, b-coronavirus, and
hemagglutinin
[38]
Virus target Respiratory system
Functional receptor ACE-2 [28]
Mode of transmission Contact, respiratory droplets, fecal oral route, and
fomites
Incubation period 2–14 days [39]
Average age affected 46% of cases occur in adults
Classic symptoms Fever, cough, sore throat, and shortness of breath [40]
Complications Pneumonia, ARDS
Mortality rate >3%; increases with age and co-morbidities [41]
Investigation/findings CT chest, lymphocytopenia
Diagnosis Identification of viral RNA by PCR [2]
Treatment Supportive care including antiviral drugs
Vaccines Under clinical trials in selected countries
Mode of reduction Social distancing, avoidance of close contact, good
personal hygiene, personal protective equipment,
sheltering at home, isolation of identified cases
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treatment. Interferons, ribavirin, lopinavir/
ritonavir, and cyclophilin inhibitors are the
most commonly administered antiviral
agents as elements of combination thera-
pies.11,18 Type I interferons were reportedly
used against MERS-CoV in various cell
lines and in rhesus macaques. Interferon-
alpha 2b and ribavirin have a synergistic
effect on SARS-CoV-1 and MERS-CoV in
cell cultures.44
Epidemiology of COVID-19
COVID-19, the disease caused by SARS-
CoV-2, is similar to that caused by SARS-
CoV-1. COVID-19 was first reported in
Wuhan (China) in December 2019. The
virus likely underwent mutation during
zoonotic transmission through pangolin,
and later infected humans. The case fatality
rate (CFR) of COVID-19 was estimated at
5.93% (3 June 2020). At the time of writing,
data from the Johns Hopkins University
(https://coronavirus.jhu.edu/map.html)
indicated a total of 20,394,078 confirmed
cases of SARS-CoV-2 worldwide with
741,808 total deaths and over 13,283,665
recovered cases.
At present, 215 countries and territories
are affected by the SARS-CoV-2 outbreak,
including the United States, Italy,
Germany, South Africa, and Nigeria. The
distribution of SARS-CoV-2 confirmed
cases, including mortality and recovery, is
shown in Figure 4. The United States,
China, and some European countries have
high case numbers and mortality rates.
Recovery rates are increasing worldwide
with higher numbers reported in China.
The COVID-19 CFR
The CFR is defined as the percentage of
deaths recorded among confirmed cases.
As of 14 April 2020, the number of deaths
among confirmed cases was estimated at
126,066 to 1,992,189, resulting in a CFR
of 6.33%. This differs from the CFR of
3.70% calculated on 15 March 2020.
However, several factors can prevent the
accurate determination of the CFR. We
compared the global CFR to the African
CFR. The highest CFR was observed in
Italy, followed by Spain and the
Netherlands (Figure 5a). In Africa, coun-
tries such as Egypt, Algeria, Burkina
Figure 4. Prevalence of COVID-19 as of 3 June 2020 (GMT 14:52). The figure shows (a) total cases, (b)
total deaths, and (c) the recovery rate per country since the time of the first case of COVID-19. Data were
downloaded from worldometers (https://www.worldometers.info/coronavirus/) and John Hopkins
University (https://github.com/CSSEGISandData/COVID-19). Graphs were produced using R-studio v3.4.4
and the ’rworldmap’ package v1.3-6.
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Faso, and Morocco had CFRs above 5%
(Figure 5b). A major challenge in the accu-
rate calculation of the CFR is the denomi-
nator (the number of confirmed cases).
Asymptomatic cases of COVID-19, patients
with mild symptoms, or individuals who are
misdiagnosed may be left out of the denom-
inator, leading to underestimation or over-
estimation of the CFR.45 High CFRs reflect
limited access to health care for the most
vulnerable patients and limitations in
health-care systems, including limited
capacity of surveillance systems to trigger
a timely response (WHO, 2020).
Estimation of the COVID-19 reproductive
number
To date, over 20 million cases of COVID-19
have been reported globally. It is important
to estimate the reproductive number for this
virus to enable accurate predictions. Two
primary factors, the reproductive ratio
(Ro) and the serial interval (SI), are essential
to estimate the rate of transmission of this
disease.
The reproductive ratio (Ro) of COVID-19. Ro
measures the degree of COVID-19 conta-
gion or infectiousness. Ro represents the
average number of people who will be
infected by one infected individual. Zhang
et al46 estimated that the median and 95%
confidence interval (CI) of Ro were about
2.28 (2.06–2.52) for early outbreaks of
COVID-19. This means that an infected
person can transmit COVID-19 to an aver-
age of two to three other people. Various
studies reported significant variations in Ro
using different datasets.47,48
Serial interval (SI). To understand the case
turnover and transmissibility of COVID-
19, the serial interval (SI) from the onset
of illness in a primary case to the onset of
illness in a secondary case is important.49
Recent studies estimated the average SI for
COVID-19 as 3.77 (2.23–4.82) days.49–51 A
shorter SI makes COVID-19 harder to con-
tain and more likely to rapidly transmit
within populations (Figure 6).
Taking the R0 and SI of COVID-19 into
consideration, it can be inferred that
approximately 4 days are required for an
infected person to transmit COVID-19. It
is highly likely that the individual can
infect approximately two or three other per-
sons, making the spread of COVID-19
extremely rapid and dangerous (Figure
7a). The extent of spread is totally depen-
dent on the Ro value (Figure 7b). If R0< 1,
each existing infection causes less than one
new infection. In this case, the disease will
decline and eventually die out. If Ro¼ 1,
each existing infection causes one new infec-
tion. The disease will remain stable in the
population, but will not result in epidemic
spread. If R0> 1, each existing infection
causes more than one new infection. The dis-
ease will spread between individuals and
Figure 5. Top 10 COVID-19 CFRs over a period of 3 months (onset to 1 April 2020). CFRs are presented
(a) globally and (b) for Africa.
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eventually lead to an outbreak. COVID-19
was regarded as an outbreak (30 January
2020) with a R0> 1 (Figure 7b).
Importantly, the R0 value of a disease
only applies when everyone in a population
is completely susceptible. This means that
no one has been vaccinated or had the dis-
ease previously, and there is no way to con-
trol the spread of the disease using
interventions such as drugs or vaccines.
Pathophysiology of COVID-19
There are currently two known modes of
COVID-19 transmission: the fecal-oral
route and respiratory droplets.6,52–56
Droplets have potential to come into con-
tact and infect a healthy person within 3 to
6 feet (1 meter). Droplets that stick to sur-
faces can survive for more than 24 hours,
remaining infectious. The virus can remain
airborne for about 3 hours, long enough to
permit transmission.
Upon infection with SARS-CoV-2, the
virus infects type II pneumocytes of
the alveoli.57 These pneumocytes are
responsible for surfactant production.
Surfactant decreases the surface tension
within alveoli and reduces the collapsing
pressure. The spike protein of the virus
binds to ACE-2 on the pneumocytes
(Figure 8) permitting virion entry into the
host cell.58 The virus hijacks the host cell’s
machinery (ribosomes) to enable transla-
tion of its þssRNA genome into different
protein molecules. The virus can also use
its RdRp to produce additional copies of
its þssRNA genome (Figure 9). The trans-
lated polyproteins are further processed
into different individual components
Figure 6. The SI of COVID-19 as of 6 March 2020. The time from the onset of symptoms in patient one
(P1) to the onset in patient two (P2) is equal to SI. The shorter the period the more dangerous and
transmissible the infectious disease, and vice versa.
Figure 7. The association between R0 and SI in COVID-19 estimators. The extent of spread is dependent
on Ro.
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within the host cell. These processes give
rise to multiple virions, which are then
released upon pneumocyte damage. In
response to this process, type II pneumo-
cytes releases specific inflammatory media-
tors that instruct macrophages to secrete
interleukins 1 and 6 (IL-1 and IL-6) and
tumor necrosis factor-alpha. These cyto-
kines cause the endothelial cells lining
blood vessels to dilate, leading to increased
capillary permeability. In response, fluids
accumulate in the alveoli leading to
edema.59 As surface tension increases, the
collapsing pressure of the alveoli increases.
A decrease in gas exchange is also observed
through this process, which in turn leads to
hypoxia and difficulty breathing (dyspnea).
This can progress to a critical condition
such as acute respiratory distress syndrome
(ARDS).
Inflammatory mediators further stimu-
late neutrophils, which release reactive
oxygen species and proteases. This process
damages the alveoli (both type 1 and 2),
leading to consolidation and alveolar col-
lapse. High levels of IL-1 and IL-6 travel
through the blood to the central nervous
system, instructing the hypothalamus to
release prostaglandins and causing fever.
Severe lung inflammation leads to systemic
inflammatory respiratory syndrome.
Progression can lead to increased capillary
permeability. The overall blood volume
decreases, and through a series of processes
involving hypotension and decreased perfu-
sion of multiple different organs, multiple
system organ failure (MSOF) can occur.
During MSOF, elevated levels of blood
urea, nitrogen, and creatinine accrue in
the kidney. The liver also releases specific
inflammatory and acute phase response
biomolecules (aspartate transaminase, ala-
nine transaminase, bilirubin, C-reactive
Protein [CRP], fibrinogen and IL-6) that
can serve as biomarkers for patients with
COVID-19.
Transmission of SARS-CoV-2 through the eyes.
There is continued research by multiple
groups into the mechanism of transmission
of SARS-CoV-2 through the eyes.
Investigations were necessary because
health care providers, including a Perking
University Physician, may have contracted
the virus while not wearing eye protection
when treating patients.61 Some researchers
have asserted that avoidance of touching
the eyes, nose or mouth with unwashed or
unsterilized hands can reduce COVID-19
transmission. The mucous membranes that
line various cavities in the body are gener-
ally most susceptible to viral transmis-
sion.62 Ocular symptoms such as viral
conjunctivitis can result from SARS-CoV-
Figure 8. Structure of SARS-COV-2 adapted from Encyclopaedia Britannica [60].
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2 upper respiratory tract infections.63 This
was confirmed in 9 of 1,099 patients in
China.64 Other research also found that 1
of 30 patients hospitalized with COVID-19
were diagnosed with conjunctivitis.65 In a
study conducted by the American
Optometric Association, COVID-19 was
linked to ocular signs and symptoms includ-
ing photophobia, irritation, conjunctival
infection and ocular discharge.66 Thus, the
superficial blood vessels of the conjunctiva
are an alleged route of exposure and trans-
mission of SARS-CoV-2.
Clinical symptoms of COVID-19
The clinical manifestations of SARS-CoV-2
are uncertain and change frequently. Some
infections are asymptomatic. Symptoms
can include respiratory distress syndrome,
pneumonia of different levels of severity,67
and sometimes death. According to the
WHO, the most common symptoms of
COVID-19 are fever, fatigue, dry continu-
ous cough, and shortness of breath.68,69
Some patients may have a runny nose,
sore throat, nasal congestion, aches and
pains, and diarrhea.70 Some patients
report a loss of sense of smell and taste.71
In some cases, symptoms are mild and sim-
ilar to those of the common cold; in such
patients, recovery can occur without any
treatment.72 The least commonly observed
symptoms include nausea or vomiting,
coughing up blood or bloody mucus, and
viral conjunctivitis causing red eyes,
Figure 9. Pathophysiology of COVID-19. The virus can be transmitted via person-to-person contact
through (1) the fecal-oral route and or (2) respiratory droplets. (3) The virion enters through the mouth,
nose or eyes and (4) infects the alveoli of the lungs. (5) The COVID-19 spike protein binds to ACE-2 on type
2 pneumocytes. (6) COVID-19 releases its genetic material (þssRNA) for processing. (7) the host
machinery, þssRNA is translated into polyproteins (8), which are further cleaved by proteinases into the
different components of the virus. (9) More RNA copies are synthesized by RNA-dependent RNA poly-
merase. (10) Proteins and RNA are assembled into a new virion in the Golgi apparatus, which is then (11)
released. (12) These processes stimulate the release of cytokines and other proteolytic enzymes, which
cause various complications such as consolidation and (13) pneumonia.
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watery discharge from the eyes, swollen eye-
lids and light sensitivity.3 Occasional upper
respiratory and gastrointestinal symptoms,
accompanied by changes vital signs such as
increased respiration (heart rate) and low
blood pressure may also be observed, espe-
cially in the elderly and among individuals
suffering from heart disease, chronic respi-
ratory conditions and diabetes.73
Additionally, patients critically ill with
COVID-19 may present with increased
venous thromboembolism including throm-
bocytopenia, elevated D-dimer, prolonged
prothrombin time and disseminated intra-
vascular coagulation (DIC). These coagula-
tion abnormalities are associated with a
systemic inflammatory response and an
imbalance between pro-coagulant and anti-
coagulants homeostasis mechanisms. and
increase the risk of mortality.74 Some of
these clinical features are also observed in
cases of DIC observed in septic patients.
These features are very distinct in
COVID-19 patients as their levels are
higher than the standards for sepsis.75,76
Diagnosis, prognosis, treatment,
and management of SARS-CoV-2
Diagnosis of SARS-CoV-2
SARS-CoV-2 causes various complications
ranging from fever, dry cough, and pneu-
monia to decreased organ perfusion leading
to MSOF. Early symptoms are similar to
those of influenza, and the first step to dif-
ferentiate COVID-19 from flu and pneumo-
nia is a nasopharyngeal swab test (viral
testing for influenza A/B).77 Quantitative
polymerase chain reaction-based (qPCR)
methods are the major diagnostic tests for
SARS-CoV-2 using nasal swab, aspirate,
sputum, or blood as samples. These
method have some limitations as they are
time consuming and have variable sensitiv-
ity (30%–80%).78–80 Another diagnostic
method is the newly approved nucleic acid
test, which is carried out based on the prin-
ciple of fluorescence PCR.81 The main goal
of SARS-CoV-2 diagnosis is to accurately
detect the virus and to minimize further
transmissions by timely isolation and treat-
ment of infected patients. Other tests (not
specific for SARS-CoV-2) used in conjunc-
tion with the methods above are based on
clinical manifestations. These include blood
tests such as complete blood count, compre-
hensive metabolic panels, basic metabolic
panels, and assessment of liver/kidney
markers and procalcitonin levels (for bacte-
rial infections). Inflammatory markers may
also be assessed including CRP, erythrocyte
sedimentation rate, IL-6, lactate dehydroge-
nase, D-dimer, ferritin, troponin and crea-
tine kinase-MB. Imaging investigations are
typically computed tomography scans: in
COVID-19 patients these often show glass
opacities, areas of consolidation, and
paving patterns in cases of severe and pro-
gressive disease. Ground glass opacities can
also be observed on chest X-ray. Finally,
ultrasound can show B-lines, pleural line
thickening, and lung consolidation. Air
bronchograms can also be used for assess-
ment. These tests are non-specific but help-
ful to determine patients’ health status.
COVID-19 patients with severe ARDS
could potentially present with pneumonia.
Pneumonia may be severe, leading to
ARDS and MSOF. It is therefore impera-
tive to mechanically ventilate the lungs to
avoid ARDS and MSOF.
Prognosis of SARS-COV-2
Although the risk factors for COVID-19
remain unclear, some risk factors put
patients at a significantly higher risk of
mortality, especially in individuals with
underlying conditions.6,35,40,82 Some medi-
cal disorders are correlated with higher
risk of mortality in COVID-19 patients.
These include, cardiovascular diseases mor-
tality risk 10.6%),41 lung disease (mortality
12 Journal of International Medical Research
risk 7.3%), type 1 and 2 diabetes (mortality
risk 6.3%), immunosuppression (e.g.,
cancer patients; mortality risk 5.6%),83–86
and age (Figure 10).87 COVID-19 mortality
rates increase with advancing age, and are
especially high in those aged>60 years.
Elevated inflammatory markers in response
to tissue damage (elevated levels of
D-dimer, ferritin, creatine kinase-MB, and
troponin) have been associated with higher
mortality rates.
Potential treatment of COVID-19
The first line of treatment for patients pre-
sented with the symptoms of COVID-19
(fever, dry cough, and shortness of breath)
is self-quarantine for at least 14 days. Cases
are monitored for progression of symptoms
such as increased fever (>40C), significant
difficulty breathing or shortness of breath,
mouth breaks, constant coughing, and
dehydration. If there is no significant
improvement in symptoms, it is advisable
to consult a clinician for confirmation of
the diagnosis and to avoid further spread
of the virus. The main treatment currently
available is supportive care. Although there
is limited information on COVID-19, it has
been linked to ARDS. For patients with
high fevers that could potentially lead to
dehydration, intravenous fluids such as
normal saline or lactated Ringer’s fluid
can be administered sparingly to prevent
lung overload. To reduce fever, antipyretic
drugs such as paracetamol or acetamino-
phen can be administered. Drugs such as
remdesivir, chloroquine, ritonavir, tocilizu-
mab, corticosteroids have been repurposed
for the treatment of COVID-19 (Figure 11),
although their clinical effectiveness has not
yet been confirmed.88–93 Unfortunately, the
use of chloroquine and derivatives such as
hydroxychloroquine, alone or in combina-
tion with other drugs, resulted in cardiac
toxicity. Investigations of these drugs were
recently suspended by the WHO.94
Mechanism of action of selected repurposed drugs
for treatment of COVID-19. The elucidation of
potential targets could lead to COVID-19-
specific treatments (Figure 11). Approaches
to anti-SARS-CoV-2 drug development
include (a) inhibition of SARS-CoV-2
entry, (b) disruption of SARS-CoV-2
þssRNA synthesis after entry, (c) inflamma-
tory response suppression, and (d) disrup-
tion of SARS-CoV-2 translation.
An FDA-approved immunosuppressive
and anti-malarial parasite drug (chloro-
quine) can inhibit the entry of COVID-19
into the endosome after binding to ACE-2
receptors, thereby preventing the release of
þssRNA for translation.89,93,95,96 Studies
also showed that hydroxychloroquine, an
analog of chloroquine, was more potent
and could be used in place of chloroquine.97
Remdesivir, a novel antiviral drug and
nucleotide analog used to treat Ebola
virus infection, is currently under clinical
development. The mechanism of the drug
is reported to be at the post viral entry
stage.89 Its mode of action is to inhibit the
RdRp, preventing synthesis of the viral
þssRNA (Figure 11 (2)). This drug is cur-
rently in phase 2 clinical trials. The protein
inhibitor ritonavir has also been proposed
for the treatment of COVID-19. This drug
interferes with the protease enzymes (pro-
teinases) by inhibiting the conversion of
polyproteins into the mature components
(spike proteins, nucleocapsids) needed
by the virus for multiplication (Figure 11
(3)). Another immunosuppressive drug,
tocilizumab, has also been repurposed for
COVID-19 because of its ability to block
IL-6 and inhibit inflammatory responses.
Corticosteroids can also decrease inflamma-
tion by inhibiting phospholipases such as
phospholipase A2, and thus suppress the
excessive production of prostaglandins
(Figure 11 (4)).
SARS-CoV-2 appears unfamiliar to the
human innate immune system. Coupled
with its emergence and its spread globally
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via human-to-human transmission, the
development of vaccines for prevention is
no longer a debate but a necessity. Several
vaccine platforms are being developed and
some have entered clinical trials. However,
approval by regulatory agencies such as the
FDA and manufacturing may take 12 to
18 months.98
Studies of the antiviral activity of
host-directed drugs and compounds have
identified two classes of molecules (protein
biogenesis inhibitors and ligands of the
Sigma1 and Sigma2 receptors) as effective
inhibitors of viral infectivity. Molecules
that target the Sigma1 and Sigma2 recep-
tors perturb the virus through different
mechanisms from translation inhibitors,
potentially including modulation of cellular
stress responses.99 The ligands haloperidol,
PB28, PD-144418, and hydroxychloroquine
are currently undergoing clinical trials in
COVID-19 patients.100 These molecules
exert their antiviral effects during viral rep-
lication by inhibiting nucleoprotein expres-
sion after viral entry has occurred. The
lack of selectivity of chloroquine and
hydroxychloroquine, including off-target
effects on the human Ether-à-go-go-
Related Gene (hERG) and other molecules,
may be related to the adverse cardiac reac-
tions that have limited their use.101 A recent
study by Gordon et al identified 332 high-
confidence SARS-CoV-2-human protein
interactions connected to multiple biologi-
cal processes, including protein trafficking,
translation, transcription and ubiquitina-
tion regulation.102 The study identified 69
ligands, including FDA approved drugs,
compounds in clinical trials, and preclinical
compounds that might theoretically have
therapeutic effects as host-directed inter-
ventions against COVID-19. To date, no
Figure 11. Selected repurposed drugs for treatment of COVID-19.
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known antiviral drugs nor vaccines against
SARS-CoV-2 with proven clinical efficacy
have been identified. Part of the reason for
the absence of such agents is limited infor-
mation regarding the molecular details of
the infection. To develop therapeutic inter-
ventions against COVID-19, it is crucial to
understand how the virus interactions with
the host during infection.
ACE-2, a potential target for COVID-19 treat-
ment. ACE-2 has been identified as the
functional receptor for SARS-CoV-2. It is
an outer membrane enzyme expressed in
vascular endothelial cells, the renal tubular
epithelium, and Leydig’s cells of the testes,
lungs, heart, kidney, and gastrointestinal
tract.59,103 It is a type-II transmembrane
metallocarboxypeptidase with its enzymati-
cally active domain exposed at the cell
surface.104 ACE-2 is a key player in the
renin-angiotensin system (RAS) and a
target for treatment of hypertension.105
ACE-2 catalyzes the cleavage of angioten-
sin II, a vasoconstrictor, into angiotensin
1–7, a vasodilator, thereby lowering blood
pressure by negatively regulating RAS.106
ACE-2 is a promising drug target for treat-
ing CoV infection as well as other cardio-
vascular diseases.5 ACE-2 confers a
protective effect against lung injury induced
by viruses by increasing the production of
angiotensin 1–7. The virus presumably
causes lung damage by reducing ACE-2
levels on cells through the process of degra-
dation and internalization.107,108 Because
studies have shown that ACE inhibitors
and angiotensin II receptor blockers could
be used to up-regulate the expression and
activity of ACE-2 in hypertensive patients,
similar strategies might reduce the severity
of COVID-19.109,110 Recent studies have
shown that the expression of human ACE-
2 is associated with SARS-CoV infection
and that genetic variations of this receptor
may contribute to susceptibility and/or
resistance against infection.111 For instance,
a single-cell RNA sequencing analysis of
ACE-2 revealed that type II alveolar cells
had higher expression of ACE-2 in eight
individual lung tissues obtained from
normal donors. ACE-2 expression was
higher in the two male samples compared
with the six female samples. Additionally,
ACE-2 expression was higher in the only
Asian male in the study compared with
Caucasian and black Americans,59which
might explain why the four German cases
showed mild clinical symptoms with no
severe illness.112 This implies that variation
in ACE-2 expression in COVID-19 patients
is likely to affect susceptibility, symptoms




The degree of spread of COVID-19 is cur-
rently about 5.3% and could potentially
increase if precautionary measures are not
considered. Global prevention of the spread
of COVID-19 is therefore a crucial and
urgent goal. To prevent further spread of
this disease, detection and isolation of indi-
viduals with COVID-19 is of the utmost
priority. Examples of measures to curb
spread include self-quarantine, isolation of
infected individuals, social distancing, good
personal hygiene (frequent hand washing
with soap and water/alcohol-based sani-
tizers and avoiding touching the eyes, nose
and the mouth), and use of personal protec-
tive equipment. Certain classes of com-
pounds, called surfactants, are contained
in soap and have the ability to neutralize
microbes such as SARS CoV-2.113This is
because soap can assemble into bubble-
like structures called micelles that trap
viral matter and other biomaterials.114
Surfactants in soap lather have their hydro-
philic parts pointing outwards and interact-
ing with solvent and their hydrophobic
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heads pointing inwards. This opens the
coronavirus outer membrane and encapsu-
lates viral molecules within micelles, thus
making insoluble viral molecules easily sol-
uble in water and effectively removing them
from hands, surfaces or other areas after
about 20 s.115 Therefore surfactants in
soap can disrupt and sequester viruses
and other contaminants while sanitizer
and disinfectants are designed to kill
SARS-CoV-2.116
Conclusion
The outbreak of SARS-CoV-2 has become
a global threat. However, information
regarding this virus remains limited. The
available information is inconsistent and
there are constant data updates, which
may contribute to variation between study
results. For more consistent and accurate
results, well-annotated data from clinical
patients and subclinical subjects in normal
populations could help to better understand
the pandemic. The information provided in
this review is based on data provided by the
Center for Systems Science and Engineering
(CSSE) at Johns Hopkins University during
specific date ranges. Key insights into the
prevalence, pathophysiology, diagnosis,
and potential treatment of SARS-CoV-2
are herein summarized. Research efforts
are being intensified to address the current
challenges in the quest for adequate treat-
ments, diagnostics, and vaccines. Clinical
studies into the genetic variation of recep-
tors such as ACE-2 in tissues and across
populations will remain an active area of
research until relevant targets and therapies
are found. While the development of ade-
quate treatments and vaccines for COVID-
19 is underway, it is advisable that good
hygiene practices including washing of
hands and social distancing should be prac-
ticed, and government guidance/guidelines
should be followed. This will help to reduce
the spread of the disease. We hope that the
insights gained from this review will enable
researchers to help patients develop accom-
modating lifestyles and improve the effi-
ciency of health care practitioners.
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